首页> 外文期刊>Clinical ophthalmology >Proliferative vitreoretinopathy: current and emerging treatments
【24h】

Proliferative vitreoretinopathy: current and emerging treatments

机译:增生性玻璃体视网膜病变:当前和新兴治疗

获取原文
           

摘要

Abstract: Proliferative vitreoretinopathy is a disease process that follows the proliferation of ectopic cell sheets in the vitreous and/or periretinal area, causing periretinal membrane formation and traction, in patients with rhegmatogenous retinal detachments. Currently, vitreous surgery is the standard treatment; however, the results aren't satisfactory given the vision loss that ensues and that redetachment is relatively common. It is becoming clearer that there exists an interplay between various cytokines/growth factors, matrix proteins, and the different cell types that drive the undesirable formation of periretinal membranes. This fundamental understanding is aiding in identifying different adjunct agents that can block the cellular events intrinsic to proliferative vitreoretinopathy. In this review, we describe the current understanding on the pathogenesis and discuss how the fundamental understanding of the biochemical/molecular events is instrumental in developing the novel treatment strategies that are also highlighted.
机译:摘要:增生性玻璃体视网膜病变是一种疾病过程,其继发于风湿性视网膜脱离的患者玻璃体和/或视网膜周围区域异位细胞片的增殖,引起视网膜周围膜的形成和牵引。目前,玻璃体手术是标准治疗方法。但是,鉴于随之而来的视力丧失和重新分离相对普遍,结果并不令人满意。越来越清楚的是,各种细胞因子/生长因子,基质蛋白与驱动视网膜周围膜不良形成的不同细胞类型之间存在相互作用。这种基本的理解有助于确定可以阻断增殖性玻璃体视网膜病变固有的细胞事件的不同辅助剂。在这篇综述中,我们描述了对发病机理的当前理解,并讨论了对生化/分子事件的基本理解如何有助于开发也被强调的新型治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号